This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generex: What Happens in India, Stays in India

"Sure, so we haven't recognized any revenue from India, so we did send them some shipments, but those were for the clinical trials, so went to expense rather than revenue right now. So once we get through the Phase IV marketing trials, we can begin to recognize revenue."

Despite what Gluskin said on the Oct. 19, 2009 conference call, there is no record on the company's Web site or on a conference call transcript from 2007 or 2008 saying that a clinical trial in India was a "condition" for Oral-lyn's approval.

And Generex's own press release of March 25, 2008, which describes the 210,000 canisters of Oral-lyn as a "commercial order" intended for an "Indian product launch," contradicts Fellows' claim on the same conference call that the shipment of Oral-lyn was intended for use in a clinical trial.

It also seems that Generex didn't disclose the halt to Indian Oral-lyn sales in SEC documents relating to the sale of more than $32 million in company securities in four separate financing deals from May-September 2009.

None of the four prospectuses filed with the SEC outlining the sale of Generex common stock and/or warrants in these four deals disclose information about the Indian government's actions with regards to Oral-lyn.

Of course, even though Oral-lyn was pulled from the market in India, the drug could get reapproved there if subsequent trials are performed and Generex reapplies for approval.

But in the meatime, for Generex, it seems like whatever happens in India, stays in India.

-- Reported by Adam Feuerstein in Boston

Related Stories:

Biotech Stock Mailbag: Generex

Biotech Stock Mailbag: Generex, Part II

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GNBT $0.01 0.00%
LLY $75.53 0.00%
MNKD $1.35 0.00%
NVO $55.79 0.00%
SNY $41.10 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs